Search company, investor...

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Beam Therapeutics

Beam Therapeutics is a company focused on the development of advanced genetic medicines in the biotechnology industry. The company's main service involves the use of CRISPR-based editing technology to develop precision genetic medicines that treat disease. It was founded in 2017 and is based in Cambridge, Massachusetts.

Headquarters Location

238 Main Street

Cambridge, Massachusetts, 02142,

United States




Research containing Beam Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Beam Therapeutics in 1 CB Insights research brief, most recently on Sep 19, 2022.

Expert Collections containing Beam Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Beam Therapeutics is included in 2 Expert Collections, including Synthetic Biology.


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Beam Therapeutics Patents

Beam Therapeutics has filed 43 patents.

The 3 most popular patent topics include:

  • molecular biology
  • biotechnology
  • genetics
patents chart

Application Date

Grant Date


Related Topics




Small nuclear RNA, Molecular biology, Genetics, Biotechnology, Genetic engineering


Application Date


Grant Date



Related Topics

Small nuclear RNA, Molecular biology, Genetics, Biotechnology, Genetic engineering



Latest Beam Therapeutics News

Eli Lilly Earns 16% Less Due to Spending on R&D and Acquisitions

Feb 8, 2024

The American laboratory Eli Lilly obtained net profits of 4.88 billion euros in 2023 compared to the profits of 5.82 billion euros recorded in the previous year, 16.1% less due to the increase in disbursements in research and development (R&D) and in acquisitions of other companies , such as Mablink Biosciences or Beam Therapeutics. Eli Lilly’s sales were 31.8 billion euros, 19.6% more than a year before, driven by sales of Mounjaro , a drug for the treatment of diabetes that could potentially be used to reduce weight, and by Verzenio, a breast cancer drug, and Jardiance, also for diabetes. Specifically, Mounjaro’s sales skyrocketed to 4.81 billion euros, compared to 449.7 million euros in 2022 . Verzenio did the same up to 3.6 billion euros from 2.31 billion euros and Jardiance, up to 2.56 billion euros from 1.92 billion euros. On the contrary, the billing of the diabetes treatment Trulicity fell to 6.65 billion euros, 4.1% less. Read more about Eli Lilly and find the most important financial news of the day with our companion app Born2Invest. Eli Lilly spent 29.5% on R&D compared to 2022 and had extraordinary expenses due to acquisitions Revenues experienced growth of 39% in the United States, up to 6,188.1 million euros , and 10% internationally, up to 2.7 billion euros. R&D costs reached 8.68 billion euros, 29.5% more , while marketing, sales and administrative costs and those attributable to sales were 6.9 billion euros and 6.6 billion of euros, respectively. These figures were 15% and 6.8% higher than those recorded twelve months ago. The sum of these headings, plus impairments and restructuring charges, amounted to 25.78 billion euros, 29.2% more. Likewise, Eli Lilly has reported that it incurred extraordinary acquisition expenses of 3.54 billion euros for the purchase of companies such as Mablink Biosciences or Beam Therapeutics, among others. As for the fourth quarter, Eli Lilly’s profit increased by 13%, to 2.04 billion euros, and income increased to 8.71 billion euros, 28.1% more. Eli Lilly has placed its income forecast for 2024 in a range of between 37.65 billion and 38.77 billion euros due to the commercialization of new drugs that will be only partially compensated by the decline of Trulicity. __ DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our  disclaimer  for more information. This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these  important disclosures . First published in  PlantaDoce . A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail. Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Beam Therapeutics Frequently Asked Questions (FAQ)

  • When was Beam Therapeutics founded?

    Beam Therapeutics was founded in 2017.

  • Where is Beam Therapeutics's headquarters?

    Beam Therapeutics's headquarters is located at 238 Main Street, Cambridge.

  • What is Beam Therapeutics's latest funding round?

    Beam Therapeutics's latest funding round is IPO.

  • How much did Beam Therapeutics raise?

    Beam Therapeutics raised a total of $222M.

  • Who are the investors of Beam Therapeutics?

    Investors of Beam Therapeutics include ARCH Venture Partners, F-Prime Capital, Eight Roads Ventures, Omega Funds, Cormorant Asset Management and 10 more.

  • Who are Beam Therapeutics's competitors?

    Competitors of Beam Therapeutics include Rznomics and 1 more.


Compare Beam Therapeutics to Competitors

Stargazer Pharmaceuticals

Stargazer Pharmaceuticals is a biopharmaceutical company focused on the development of treatment options for rare eye diseases.

ShapeTX Logo

ShapeTX operates as a biotechnology company. It creates ribonucleic acid (RNA) and protein targeting platforms focused on the cure of human diseases. It works in the field of programmable ribonucleic acid (RNA) medicines to repair the genetic causes of diseases. The company was founded in 2019 and is based in Seattle, Washington.

Ascidian Therapeutics Logo
Ascidian Therapeutics

Ascidian Therapeutics is a company focused on the development of RNA therapeutics in the biotechnology industry. The company's main service involves the creation of a new class of medicines that address the underlying causes of disease by editing and replacing human exons at the RNA level, inspired by the natural process of RNA trans-splicing and alternative splicing in sea squirts. Ascidian Therapeutics primarily serves the healthcare sector, with a particular focus on rare diseases. It was founded in 2020 and is based in Boston, Massachusetts.

SpliceBio Logo

SpliceBio is a biotechnology company. It assembles and develops a technology to create protein-based medicines. It produces protein-based therapeutics through patented technology that enables the development of therapeutic proteins such as antibody-drug conjugates with research and development (R&D) success rates and therapeutic properties. It was founded in 2020 and is based in Barcelona, Spain.


Rznomics is a company focused on the development of biopharmaceuticals in the healthcare and biotechnology industry. The company's main services include the development of treatments for oncology, degenerative disease, and genetic disease based on RNA platform technology. The company primarily sells to the healthcare industry. It was founded in 2017 and is based in Yongin-si, South Korea.

Applied Genetic Technologies

Applied Genetic Technologies (NASDAQ: AGTC) is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. The company was founded in 1999 and is based in Alachua, Florida.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.